LPL Financial
PRME icon

LPL Financial’s Prime Medicine PRME Stock Holding History

LPL Financial’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,000
Closed -$24.7K – 5952
2025
Q2 		$24.7K Hold
10,000
– – ﹤0.01% 5443
2025
Q1 		$19.9K Buy
+10,000
New +$25.5K ﹤0.01% 5255

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

LPL Financial's PRME Position: Q2 2026 in Review

LPL Financial increased its Prime Medicine (PRME) stake by 39% in Q2 2026, buying an estimated $85.5K and bringing the position to 92,174 shares worth $340K. The position accounts for ﹤0.01% of the portfolio, ranked #5344.

LPL Financial first reported a position in PRME in Q3 2025 and has held it in 4 quarters since. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • LPL Financial held 92,174 shares of Prime Medicine worth $340K as of Q2 2026.
  • LPL Financial bought 25,750 Prime Medicine shares in Q2 2026, an estimated $85.5K.
  • Prime Medicine made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #5344 holding.
  • LPL Financial first reported a position in Prime Medicine in Q3 2025 and has held it in 4 quarters since.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.